A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, versus Investigator’s Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Project: Research

NMA HREC Reference Number: 90307
NMA SSA Reference Number: SSA/90307/MonH-2023-355207(v1)
Monash Health Local Reference: RES-22-0000-597A

Status	Active
Effective start/end date	22/05/23 → 21/05/28

Project Details